No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Emtricitabine/tenofovir-DF does not affect the zolmitriptan metabolic pathway.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking